Prosecution Insights
Last updated: November 04, 2026
Application No. 18/805,278

TAMPONADE DEVICE

Non-Final OA §102§103§112
Filed
Aug 14, 2024
Examiner
MENDEZ, KATHERINE H
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Myodynamics LLC
OA Round
3 (Non-Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
293 granted / 437 resolved
-3.0% vs TC avg
Strong +33% interview lift
Without
With
+32.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
44 currently pending
Career history
483
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
41.6%
+1.6% vs TC avg
§102
14.9%
-25.1% vs TC avg
§112
35.6%
-4.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 437 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/08/2026 has been entered. This office action is responsive to the amendment filed on 10/08/2026. As directed by the amendment: claims 1 and 3 have been amended and claims 2, 5-11, and 14-20 have been cancelled. Thus, claims 1, 3, 4, 12, and 13 are presently pending in this application. Response to Arguments Applicant’s arguments with respect to claim(s) 1 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 recites “wherein the sheath member comprises an elongated cylindrical tube, wherein the hollow cavity is configured with a first dimension, the first dimension of the hollow cavity corresponding to the inner diameter of the hollow cavity, and wherein the hollow cavity of the first dimension allows insertion of the guidewire therein” however independent claim 1 recites “an inner diameter of the hollow cavity is configured in conformity with the guidewire such that only the guidewire is inserted through the hollow cavity” which fully encompasses the scope of what is recited in claim 3. The only limiting portion of claim 3 is “wherein the sheath member comprises an elongated cylindrical tube” and The Office recommends amending claim 3 to just recite that portion. Appropriate correction is required. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3, 4, and 13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Bergin et al. (US 20080015481 A1). Regarding claim 1 Bergin discloses (fig. 3-4) a tamponade device, comprising: a sheath member 60 comprising a hollow cavity 76 defined along a length of the sheath member 60 (see fig. 3 and [0054]), the hollow cavity configured to allow insertion of a guidewire 20 therein (see fig. 3 and [0055]), wherein an inner diameter of the hollow cavity 76 is configured in conformity with the guidewire (see fig. 3 showing the cavity and guidewire being a similar shape) such that only the guidewire is inserted through the hollow cavity (see [0054]-[0058] which describes the use and only a guidewire is inserted therein), wherein the sheath member 60 is configured to be positioned at a vascular access point of a subject over the guidewire 20 deployed in a lumen of a blood vessel (see fig. 3 and [0057]), and wherein the sheath member 60 is configured with a predefined diametrical size (size of 64) that impedes the tamponade device from being deployed into the lumen of the blood vessel through the vascular access point of the subject, thereby positioning the sheath member at the vascular access point to occlude the vascular access point of the blood vessel (see fig. 3, [0057], [0077], and [0078]), and wherein the predefined diametrical size (size of 64) corresponds to an outer diameter of the sheath member 60 (see fig. 3), and wherein the outer diameter of the sheath member is greater than a size of the vascular access point (see fig. 3), thereby impeding the tamponade device from being deployed into the lumen of the blood vessel through the vascular access point (see fig. 3). Regarding claim 3 Bergin further discloses (fig. 3-4) the sheath member 60 comprises an elongated cylindrical tube 68, wherein the hollow cavity 76 is configured with a first dimension, the first dimension of the hollow cavity corresponding to the inner diameter of the hollow cavity (see fig. 3), and wherein the hollow cavity of the first dimension allows insertion of the guidewire therein (see fig. 3 and [0057]). Regarding claim 4 Bergin further discloses (fig. 3-4) the sheath member 60 when positioned at the vascular access point is configured to apply focal pressure at one of a skin level 44 of the subject and the vascular access point of the subject, thus resulting in hemostasis at the vascular access point (See fig. 3 and [0077]). Regarding claim 13 Bergin further discloses (fig. 3-4) the sheath member 60 is configured to be positioned at the vascular access point to occlude the lumen of the blood vessel based on a serial dilation induced by a dilator device 10 at the vascular access point (see fig. 3, [0057], [0077], and [0078]). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 12 is rejected under 35 U.S.C. 103 as being unpatentable over Bergin in view of Pipenhagen (US 20090171387 A1). Regarding claim 12, Bergin discloses the claimed invention substantially as claimed, as set forth above for claim 1. Bergin is silent regarding the sheath member is made of biocompatible plastic materials. However Pipenhagen, in the same filed of endeavor, teaches (fig. 2) a sheath member 50 that is made of biocompatible plastic materials (see [0040]). Therefore it would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to modify Bergin to have the sheath member is made of biocompatible plastic materials as taught by Pipenhagen, for the purpose of having the device made of a medical grade material to reduce reactions from the body when the device is used (see Pipenhagen [0040]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE H MENDEZ whose telephone number is (571)272-9503. The examiner can normally be reached Monday - Friday 8 am-4:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at (571) 272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KATHERINE H MENDEZ/Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Show 1 earlier event
Dec 10, 2025
Non-Final Rejection mailed — §102, §103, §112
Mar 06, 2026
Response Filed
Jun 02, 2026
Final Rejection mailed — §102, §103, §112
Sep 28, 2026
Examiner Interview Summary
Sep 28, 2026
Applicant Interview (Telephonic)
Oct 08, 2026
Request for Continued Examination
Oct 15, 2026
Response after Non-Final Action
Oct 20, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778621
MILLING DEVICE FOR SURGERY
4y 6m to grant Granted Nov 03, 2026
Patent 12778579
SUTURE APPARATUS, SYSTEM, AND METHOD
3y 0m to grant Granted Nov 03, 2026
Patent 12778623
Atherectomy Devices and Methods
1y 6m to grant Granted Nov 03, 2026
Patent 12773204
MULTIPLE-FIRING SUTURE FIXATION DEVICE AND METHODS FOR USING AND MANUFACTURING SAME
4y 0m to grant Granted Oct 27, 2026
Patent 12765877
LIGATING CLIP FOR CONTINUOUS FIRING
2y 9m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
99%
With Interview (+32.9%)
3y 4m (~1y 1m remaining)
Median Time to Grant
High
PTA Risk
Based on 437 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month